文献速递青光眼

基于协作初始青光眼治疗研究症状与健康问题检查表开发青光眼患者18条目症状负担测量工具

Development of an 18-Item Measure of Symptom Burden in Patients With Glaucoma From the Collaborative Initial Glaucoma Treatment Study's Symptom and Health Problem Checklist.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

基于协作初始青光眼治疗研究(CIGTS)的症状与健康问题检查表(SHPC),在607例新诊断开角型青光眼患者中开发出18条目简版(SHPC-18),包含局部眼部与视觉功能两个分量表,信度良好,与视野严重度和NEI-VFQ25相关,能区分青光眼严重程度并对治疗有反应。

要点

  • SHPC-18含局部眼部与视觉功能两个分量表,Cronbach α分别为0.83和0.89,且随时间保持稳定。
  • 两个分量表评分均与NEI-VFQ25总分相关(r=-0.41和r=-0.59),并与所有分量表评分相关(P<.01)。
  • 基线重度青光眼患者局部眼部与视觉功能评分均高于轻度患者(P<.05),小梁切除术者局部眼部症状报告频率高于局部用药者(P<.001)。

核心结论

  • SHPC-18是可靠、有反应性且心理测量学稳健的青光眼相关患者报告症状测量工具,能对治疗有反应并区分青光眼严重程度。
  • 这一原始SHPC的简版可能有助于临床和研究环境更好地理解青光眼症状对患者日常生活的影响。

研究设计与样本

  • 本研究为测量开发研究,评估43条目SHPC的因素结构,数据来自CIGTS参与者在基线和此后每6个月采集。
  • 共纳入607例在美国14个临床中心入组的新诊断开角型青光眼患者,视野检查平均偏差(SD)为−5.5(4.3)dB。
  • 数据采集时间为1993年10月至1997年4月。

主要发现

  • 607例参与者入组时平均(SD)年龄57.5(10.9)岁,男性334例(55.0%),女性273例(45.0%),非裔美国人231例(38.1%)。
  • 探索性因素分析和纵向增长模型确定局部眼部与视觉功能两个症状分量表,平均加权内部一致性Cronbach α分别为0.83和0.89,且随时间保持稳定。
  • 局部眼部与视觉功能分量表评分均与NEI-VFQ25总分相关(r=−0.41和r=−0.59),并与所有分量表评分相关(P<.01)。
  • 基线时重度青光眼患者局部眼部评分均值(SD)为4.68(6.62),轻度患者为3.07(5.60);视觉功能评分均值(SD)重度为8.44(11.45),轻度为4.42(8.94);P<.05。
  • 小梁切除术患者报告任何局部眼部症状的频率高于局部用药患者,例如12个月时分别为269例中153例(56.9%)与276例中11例(40.9%),P<.001。

关键数值与推荐

  • 局部眼部分量表Cronbach α为0.83,视觉功能分量表Cronbach α为0.89。
  • 局部眼部评分与NEI-VFQ25总分r=−0.41,视觉功能评分与NEI-VFQ25总分r=−0.59。
  • 基线重度与轻度青光眼局部眼部评分4.68(6.62)vs 3.07(5.60),视觉功能评分8.44(11.45)vs 4.42(8.94),P<.05。
  • 12个月时小梁切除术组269例中153例(56.9%)报告任何局部眼部症状,局部用药组276例中11例(40.9%)报告,P<.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Administration of a brief questionnaire to evaluate glaucoma symptoms would lend useful information for patient care. OBJECTIVES: To develop a shortened glaucoma symptom measure based on the Collaborative Initial Glaucoma Treatment Study (CIGTS) Symptom and Health Problem Checklist (SHPC) and evaluate its psychometric properties. DESIGN, SETTING, AND PARTICIPANTS: This measure development study evaluated the factor structure of the 43-item SHPC that was obtained from CIGTS participants at baseline and every 6 months thereafter. These 607 participants were enrolled at 14 clinical centers in the United States and had newly diagnosed open-angle glaucoma. Their mean deviation (SD) from visual field testing was −5.5 (4.3) dB. Data were collected from October 1993 through April 1997. MAIN OUTCOMES AND MEASURES: The factor structure of the SHPC, confirmatory factor analysis of the resulting 18-item questionnaire (SHPC-18), the reliability of the SHPC-18, and associations of the 2 symptom subscales (Local Eye and Visual Function) of the SHPC-18 with visual field severity and 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ25) subscales. RESULTS: Among the 607 participants (mean [SD] age at enrollment, 57.5 [10.9] years), 334 (55.0%) were men and 273 (45.0%) were women; 231 (38.1%) were African American. Exploratory factor analysis and longitudinal growth modeling documented Local Eye and Visual Function symptom subscales. Cronbach α values for mean weighted internal consistency were 0.83 and 0.89 for the Local Eye and Visual Function subscales, respectively, and remained stable over time. Scores on each subscale significantly correlated with the NEI-VFQ25 total score (r = −0.41 and r = −0.59, respectively) and with all subscale scores (P < .01). Participants with more severe glaucoma had higher (worse) mean (SD) scores than those with mild glaucoma at baseline on the Local Eye (4.68 [6.62] vs 3.07 [5.60]) and Visual Function (8.44 [11.45] vs 4.42 [8.94]; P < .05) SHPC-18 subscales. Participants who underwent trabeculectomy reported a higher frequency of any Local Eye symptoms than those treated with topical medications (eg, at 12 months, 153 of 269 [56.9%] vs 11 of 276 [40.9%]; P < .001). CONCLUSIONS AND RELEVANCE: These results suggest that the SHPC-18 is a reliable, responsive, and psychometrically sound measure of patient-reported, glaucoma-related symptoms. The measure is responsive to treatment and discriminates the severity of glaucoma. This shorter version of the original SHPC measure may be useful in clinical and research settings to better understand the influence of glaucoma symptoms on patients’ daily life.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Musch DC, Tarver ME, Goren MJ, et al. Development of an 18-Item Measure of Symptom Burden in Patients With Glaucoma From the Collaborative Initial Glaucoma Treatment Study's Symptom and Health Problem Checklist. JAMA Ophthalmol. 2017. PMID: 29098286. doi:10.1001/jamaophthalmol.2017.4574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。